Evidence map›Paper›PMID 41079792›Full record

ArticleJournal of pharmaceutical analysis2025

Traditional Chinese medicine-facilitated redox-labile paclitaxel dimer nanoprodrug for efficient chemoimmunotherapy.

Fan Li, Wenrui Wang, Weisheng Xu, WanYing Li, Yudi Lu, Rui Wang, Zhonggui He, Zhihui Feng, Jiabing Tong, Zhenbao Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fan LiThe First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, 230031, China.
Wenrui WangAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, 233004, China.
Weisheng XuThe First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
WanYing LiSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China.
Yudi LuSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China.
Rui WangSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China.
Zhonggui HeWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Zhihui FengSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China.
Jiabing TongThe First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, 230031, China.
Zhenbao LiSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various therapeuti modailities have been engineered for lung cancer treatment, but their clinic application is severely impeded by the poor therapy efficiency and immunosuppressive microenvironment. Herein, we fabricated a library of small molecule redox-labile nanoparticles (NPs) (i.e., diPTX-2C NPs, diPTX-2S NPs, and diPTX-2Se NPs) by the self-assembly of dimer paclitaxel (PTX) prodrug, and then utilized these NPs with the traditional Chinese medicine (TCM) Qi-Yu-San-Long-Fang (Q) for effective chemoimmunotherapy on Lewis lung carcinoma (LLC)-bearing mice models. Under the high concentration of glutathione (GSH) and H

Indexed as

ChemoimmunotherapyImmunosuppressive microenvironmentLung cancerPaclitaxel nanoprodrugQi-Yu-San-long-Fang

Identifiers

PMID41079792
PMCPMC12513003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.